Identification of Epigenetic Risk Factors for Ischemic Complication During the TAVR Procedure in the Elderly (METHYSTROKE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02972008|
Recruitment Status : Recruiting
First Posted : November 23, 2016
Last Update Posted : May 16, 2018
Over the past ten years, the number of endovascular procedures has increased by 5% per year in Europe with the development of interventional cardiology, such as percutaneous coronary angioplasty, aortic valve replacements (TAVR), and vascular endoprosthesis.
The neurological lesions detected on cerebral MRI caused by these endovascular procedures are frequent with an incidence of about 30-70%. These events, although subclinical, have an impact on morbidity and mortality and especially on long-term cognitive decline.
TAVR is the reference treatment for symptomatic elderly patients with stenosis of the aortic valve, considered by a multidisciplinary "Heart Team" as at high surgical risk due to comorbidities, age and high perioperative risk scores ( Euroscore 2 and STS scores). Despite the net clinical benefit, an increase of silent neurological events was detected on post-procedural cerebral MRI with an incidence of approximately 70%.
The epigenetic involvement in the occurrence of ischemic cerebral lesions is still largely unknown. Epigenetic mechanisms, such as DNA methylation, can be associated with aging processes and modulate the risk of developing cerebrovascular pathologies. They are likely to provide new biomarkers that predict the risk of brain damage.
Hypomethylation of leukocyte DNA is directly related to atherosclerosis in humans. This hypomethylation of DNA would represent an easily measurable marker reflecting the presence and progression of atherosclerosis. Because atherosclerotic lesions often precede the clinical manifestation of ischemic cardiovascular disease, such as ischemic heart disease and stroke, DNA hypomethylation could be used to identify individuals at risk for cerebrovascular events.
The investigator hypothesize that hypomethylation of leukocyte DNA can predict the risk of developing new ischemic brain lesions especially after a TAVI procedure.
|Condition or disease|
|Cognitive Decline Stroke|
This is a french multicenter prospective cohort study. Patients with severe symptomatic aortic stenosis referred for a TAVI procedure to the cardiology departments of the university hospitals of Lille, Caen, Amiens and the Pitié-Salpêtrière hospital (APHP) are analyzed for inclusion in this prospective study. The cases are selected after a discussion between the members of the local TAVI "Heart Team" (cardiologists, cardiac surgeons, anesthetists), as recommended by the guidelines of the European Society of Cardiology. Written consent is obtained in accordance with international recommendations for clinical research (Helsinki Declaration). Participation in the study is proposed to patients during preoperative consultation.
The collection of clinical data, including postoperative cerebral MRI, is collected prospectively during hospitalization and during the clinical visit to each institution at one year. An evaluation of cognitive function is performed by a mini-mental state (MMS) the day before the TAVI intervention and then at 1 year. The study ends after the last evaluation. A cerebral MRI is performed within 1-3 days after the TAVI procedure to detect new cerebral ischemic lesions (emboli).
Blood samples will be taken during the patient's stay: the day before TAVI, during the procedure and after the TAVI procedure at day 1 and day 4.
The follow-up visit to 1 year will be conducted by cardiologists or cardiac surgeons with an evaluation of the cognitive function by the mini-mental state (MMS).
|Study Type :||Observational|
|Estimated Enrollment :||542 participants|
|Official Title:||Identification of Epigenetic Risk Factors for Ischemic Complication During the TAVR Procedure in the Elderly|
|Actual Study Start Date :||March 9, 2017|
|Estimated Primary Completion Date :||February 2019|
|Estimated Study Completion Date :||February 2022|
Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) having at least one new cerebral ischemic lesion on postoperative cerebral MRI
No Cerebral Lesion
Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) with no cerebral ischemic lesion on postoperative cerebral MRI
- Pre-operative leukocyte DNA methylation rate (cerebral lesions) [ Time Frame: The day before the TAVI procedure ]This rate will be measured by the LUMA method in patients treated with TAVI according to the presence of at least one new cerebral ischemic lesion on postoperative MRI
- Variation of the leukocyte DNA methylation rate during the TAVI procedure [ Time Frame: At time between the pre (day-1) and postprocedural (day 1) samples ]This rate will be measured by the LINE-1 method in all patients
- Pre-operative leukocyte DNA methylation rate (stroke/TIA) [ Time Frame: The day before the TAVI procedure ]This rate will be measured by the LUMA method in patients treated with TAVI according to the presence of a neurological deficit (stroke, transient ischemic attack)
- Mortality [ Time Frame: At 1 year after TAVI procedure ]The mortality in patients treated with TAVI according to the presence of at least one new ischemic cerebral lesion detected on postoperative cerebral MRI and / or postprocedural ischemic stroke / TIA
- MMS score variation [ Time Frame: At day-1 before TAVI procedure and at 1 year after TAVI procedure ]The MMS score variation is compared according to the presence or not of at least one new cerebral ischemic lesion
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02972008
|Contact: Nicolas Debry, MD||+33 3 20 44 59 62 ext +email@example.com|
|Hôpital cardiologie, CHRU||Recruiting|
|Principal Investigator: Nicolas Debry, MD|
|Principal Investigator:||Nicolas Debry, MD||University Hospital, Lille|